In:
Cancer, Wiley, Vol. 124, No. 11 ( 2018-06), p. 2337-2346
Abstract:
This study presents the results of a phase 2 trial of veliparib plus temozolomide for patients with metastatic colon cancer. The combination has been found to be well tolerated, with disease control achieved in 24% of patients (with 2 confirmed partial responses). There is a suggestion of worse outcomes for patients with a mismatch repair deficiency, and there is no correlation between phosphatase and tensin homolog deleted on chromosome 10 or O(6)‐methylguanine‐DNA methyltransferase protein expression and disease control.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v124.11
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1